Aptevo Therapeutics Total Assets 2014-2022 | APVO

Aptevo Therapeutics total assets from 2014 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Aptevo Therapeutics Annual Total Assets
(Millions of US $)
2021 $57
2020 $54
2019 $53
2018 $67
2017 $117
2016 $92
2015 $128
2014 $120
2013 $0
Aptevo Therapeutics Quarterly Total Assets
(Millions of US $)
2022-03-31 $45
2021-12-31 $57
2021-09-30 $64
2021-06-30 $71
2021-03-31 $69
2020-12-31 $54
2020-09-30 $37
2020-06-30 $19
2020-03-31 $25
2019-12-31 $53
2019-09-30 $61
2019-06-30 $66
2019-03-31 $81
2018-12-31 $67
2018-09-30 $79
2018-06-30 $90
2018-03-31 $100
2017-12-31 $117
2017-09-30 $131
2017-06-30 $87
2017-03-31 $98
2016-12-31 $92
2016-09-30 $101
2016-06-30 $118
2016-03-31 $0
2015-12-31 $0
2015-09-30 $0
2015-06-30 $0
2014-12-31 $120
2013-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.023B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00